EA201400237A1 - Фолатные конъюгаты альбуминсвязывающих частиц - Google Patents

Фолатные конъюгаты альбуминсвязывающих частиц

Info

Publication number
EA201400237A1
EA201400237A1 EA201400237A EA201400237A EA201400237A1 EA 201400237 A1 EA201400237 A1 EA 201400237A1 EA 201400237 A EA201400237 A EA 201400237A EA 201400237 A EA201400237 A EA 201400237A EA 201400237 A1 EA201400237 A1 EA 201400237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
folated
albumins
conjugates
radionuclide
diagnostic
Prior art date
Application number
EA201400237A
Other languages
English (en)
Inventor
Роже Шибли
Рудольф Мозер
Кристина Магдалена Мюллер
Харриет Стратерз
Виола Грён
Симон Менсах Аметамей
Синди Рамона Фишер
Original Assignee
Мерк Э Сие
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Э Сие filed Critical Мерк Э Сие
Publication of EA201400237A1 publication Critical patent/EA201400237A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Abstract

Настоящее изобретение относится к новым трехфункциональным фолатным конъюгатам, содержащим фолат, альбуминовое связующее и терапевтическую или диагностическую часть на основе радионуклида, а также к их фармацевтическим композициям, к способу их получения и к их применению для диагностических и терапевтических применений в медицине, таких как диагностическая радионуклидная визуализация и радионуклидная терапия.
EA201400237A 2011-08-17 2012-08-10 Фолатные конъюгаты альбуминсвязывающих частиц EA201400237A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11177732 2011-08-17
PCT/EP2012/065702 WO2013024035A1 (en) 2011-08-17 2012-08-10 Folate conjugates of albumin-binding entities

Publications (1)

Publication Number Publication Date
EA201400237A1 true EA201400237A1 (ru) 2014-08-29

Family

ID=46650547

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400237A EA201400237A1 (ru) 2011-08-17 2012-08-10 Фолатные конъюгаты альбуминсвязывающих частиц

Country Status (11)

Country Link
US (1) US9295739B2 (ru)
EP (1) EP2766364A1 (ru)
JP (1) JP6152104B2 (ru)
KR (1) KR102036199B1 (ru)
CN (1) CN103732595B (ru)
AU (1) AU2012296937B2 (ru)
CA (1) CA2839647C (ru)
EA (1) EA201400237A1 (ru)
IL (1) IL230758B (ru)
WO (1) WO2013024035A1 (ru)
ZA (1) ZA201400174B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776382B1 (en) * 2011-08-22 2018-09-19 Merck & Cie 18f-saccharide-folates
CN104897627B (zh) * 2015-02-04 2017-07-11 浙江工商大学 一种基于分子识别的荧光检测叶酸的方法
WO2016168471A1 (en) * 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
EP3429575A4 (en) 2016-03-16 2019-10-23 Purdue Research Foundation AGAINST CARBOANHYDRASE-IX DRUGS AND METHODS
EP3429637A4 (en) 2016-03-16 2020-03-11 Endocyte, Inc. CONJUGATES OF CARBONIC ANHYDRASE IX INHIBITORS AND USES THEREOF
US11225496B2 (en) 2016-08-10 2022-01-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
CN110612126B (zh) * 2017-04-05 2023-11-03 康奈尔大学 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
EP3630204A1 (en) 2017-05-24 2020-04-08 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof
CA3076259A1 (en) * 2017-09-19 2019-03-28 The Governors Of The University Of Alberta Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
CN112409436B (zh) * 2020-11-06 2022-02-18 厦门大学 一种放射性核素标记的***受体分子靶向化合物及其应用
WO2024025845A1 (en) * 2022-07-25 2024-02-01 Sorrento Therapeutics, Inc. Folate-conjugated drugs and uses thereof
WO2024051794A1 (zh) * 2022-09-09 2024-03-14 同宜医药（苏州）有限公司 放射性核素偶联药物及其药物组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136159A (en) 1977-02-28 1979-01-23 New England Nuclear Corporation Radioassay of folates
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5919934A (en) 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PT2151250E (pt) 2002-05-06 2013-12-09 Endocyte Inc Agentes de formação de imagem direccionados para vitamina
ES2566761T3 (es) 2002-05-30 2016-04-15 The Scripps Research Institute Ligación de azidas y acetilenos catalizada por cobre
JP2008540338A (ja) 2005-04-27 2008-11-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 分子画像化プローブのクリックケミストリー合成法
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
CA2670371C (en) * 2007-04-11 2015-01-20 Merck Eprova Ag 18f-labelled folates
US20100143249A1 (en) * 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
EP2231194B1 (en) 2007-12-04 2017-02-22 Alnylam Pharmaceuticals Inc. Folate-irna conjugates

Also Published As

Publication number Publication date
JP2014531407A (ja) 2014-11-27
JP6152104B2 (ja) 2017-06-21
CA2839647C (en) 2022-08-16
EP2766364A1 (en) 2014-08-20
CN103732595A (zh) 2014-04-16
AU2012296937B2 (en) 2017-10-12
AU2012296937A1 (en) 2014-02-20
ZA201400174B (en) 2015-09-30
KR20140052027A (ko) 2014-05-02
KR102036199B1 (ko) 2019-10-24
IL230758A0 (en) 2014-03-31
US20140234216A1 (en) 2014-08-21
WO2013024035A1 (en) 2013-02-21
CA2839647A1 (en) 2013-02-21
CN103732595B (zh) 2017-02-08
US9295739B2 (en) 2016-03-29
IL230758B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
EA201400237A1 (ru) Фолатные конъюгаты альбуминсвязывающих частиц
CY1122165T1 (el) Αντισωματα anti-cd38
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201290712A1 (ru) Альфа-излучающие комплексы
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
CY1121736T1 (el) Άλατα aramchol
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
BR112013028908A2 (pt) anticorpos c-kit e usos dos mesmos
GT201200271A (es) Proteínas que se unen al tnf-a
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
IN2015DN03854A (ru)
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
MY191932A (en) Chitosan-derived compositions